pharma · Duchenne Muscular Dystrophy · Muscular Dystrophies · CAPR
CAPRICOR THERAPEUTICS
CAPRICOR THERAPEUTICS, INC.
CAPRICOR THERAPEUTICS is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker CAPR. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophies, Covid19, Dil
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2005
- Employees
- 240
- Programs
- 8
- Drugs
- 6
- Patents
- 43
Allogeneic Cardiosphere-Derived Cells (CAP-1002)
Phase 2 · small molecule · Duchenne Muscular Dystrophy
Allogeneic Cardiosphere-Derived Cells (CAP-1002) for Duchenne Muscular Dystrophy is a Phase 2 program (small_molecule) at CAPRICOR THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).
Internal code CAP-1002-DMD-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CAPRICOR THERAPEUTICS, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Duchenne Muscular Dystrophy
- Status
- completed
- Trials
- 2